# An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer

> **NCT00570713** · PHASE2 · COMPLETED · sponsor: **Morphotek** · enrollment: 155 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** MORAb-009
- **DRUG:** Placebo
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00570713
- **Lead sponsor:** Morphotek
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2015-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00570713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00570713, "An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT00570713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*